A version of the Alzheimer’s disease drug Leqembi that can be given with a simpler, under-the-skin injection is equally effective as the currently approved intravenous infusion, according to study results presented Wednesday by its maker, Eisai.
But hopes that the subcutaneous injection would also cause lower rates of brain swelling and bleeding — the drug’s most worrisome side effects — were not borne out in the study.
The findings were presented during an evening symposium at the 2023 Clinical Trials on Alzheimer’s Disease (CTAD) meeting, underway in Boston.